S Vadlamudi - Concepedia

Author

S Vadlamudi

Also Known As

S VADLAMUDI, S Vadlamudi, S. VADLAMUDI, S. Vadlamudi, Sai Navya Vadlamudi, Sai Vadlamudi, Srikrishna Vadlamudi, Sujitha Vadlamudi, Vadlamudi, S

Publications

583

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute

About

S Vadlamudi is an author at National Cancer Institute specializing in medicine, pharmacology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	15	521
2	Health Sciences	4	4	119
3	Allergy	2	2	87
4	Natural Sciences	1	1	48
5	Biochemistry	1	1	48

S Vadlamudi

Publications

521

Citations

H-Index

Page 1

	Year	Citations
IMMUNOLOGICAL ALTERNATION OF LEUKEMIC CELLS <i>In Vivo</i> AFTER TREATMENT WITH AN ANTITUMOR DRUG Enzo Bonmassar, Anna Bonmassar, S Vadlamudi, Proceedings of the National Academy of Sciences Cell TherapyL1210 LeukemiaGeneralized LeukemiaImmunologyPathology	1970	121
Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide. Enzo Bonmassar, Anna Bonmassar, S Vadlamudi, PubMed Hematological MalignancyCancer ImmunosurveillanceAllergyL1210 LeukemiaSpontaneous Mutants	1972	71
Antigenicity of L1210 leukemic sublines induced by drugs. A Nicolin, S Vadlamudi, Abraham Goldin PubMed Hematological MalignancyLymphoid NeoplasiaLeukemia L1210Cancer ImmunosurveillanceMedicine	1972	63
Synthesis and biologic evaluation of 7-hydroxymethotrexate, 7-methylaminopterin, and 7-methylmethotrexate David Farquhar, Ti Li Loo, S Vadlamudi Journal of Medicinal Chemistry Pharmaceutical ScienceBiologic EvaluationAltmetric Attention ScorePharmaceutical ChemistryMolecular Pharmacology	1972	48
Effect of combination treatment with cyclophosphamide and isogeneic or allogeneic spleen and bone marrow cells in leukemic (l1210) mice S Vadlamudi, M Padarathsingh, Enzo Bonmassar, International Journal of Cancer Cell TherapyImmunologyImmune RegulationPharmacotherapyImmunotherapeutics	1971	34
Influence of tumor-host differences at a single histocompatibility locus (H-1) on the antileukemic effect of 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC 409962). Enzo Bonmassar, Gustavo Cudkowicz, S Vadlamudi, PubMed ImmunologyImmunoeditingPathologyNsc 409962Immunotherapy	1970	29
Preparation and antitumor activity of derivatives of 1-phenyl-3,3-dimethyltriazene Ying‐Tsung Lin, Ti Li Loo, S Vadlamudi, Journal of Medicinal Chemistry Pharmaceutical ScienceAntitumor ActivityAltmetric Attention ScoreOrganic ChemistryPharmacotherapy	1972	26
Schedule-dependent therapeutic synergism for L-asparaginase and methotrexate in leukemic (L5178Y) mice. S Vadlamudi, b udhay krishna, Vinodini Reddy, PubMed Hematological MalignancyMolecular PharmacologyOncologyTherapeutic SynergismMedicine	1973	26
Effect of combination treatment with 5-azacytidine and cytidine on the life-span and spleen and bone marrow cells of leukemic (L1210) and nonleukemic mice. S Vadlamudi, Javeriya Choudry, V.S. Waravdekar, PubMed Antileukemic EffectImmunologyNonleukemic MicePharmacotherapyExperimental Pharmacology	1970	19
Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors. Garibjanian Bt, Johnson Rk, I Kline, PubMed ImmunologyTherapeutic ActivityTherapeutic ResponseFtorafur TreatmentMurine Tumors	1976	17

Page 1